Effect of Pycnogenol® on attention-deficit hyperactivity disorder (ADHD): study protocol for a randomised controlled trial

Annelies A J Verlaet, Berten Ceulemans, Helene Verhelst, Dirk Van West, Tess De Bruyne, Luc Pieters, Huub F J Savelkoul, Nina Hermans, Annelies A J Verlaet, Berten Ceulemans, Helene Verhelst, Dirk Van West, Tess De Bruyne, Luc Pieters, Huub F J Savelkoul, Nina Hermans

Abstract

Background: Methylphenidate (MPH), the first choice medication for attention-deficit hyperactivity disorder (ADHD), is associated with serious adverse effects like arrhythmia. Evidence on the association of ADHD with immune and oxidant-antioxidant imbalances offers potential for antioxidant and/or immunomodulatory nutritional supplements as ADHD therapy. One small randomised trial in ADHD suggests, despite various limitations, therapeutic benefit from Pycnogenol®, a herbal, polyphenol-rich extract.

Methods: This phase III trial is a 10-week, randomised, double-blind, placebo and active treatment controlled multicentre trial with three parallel treatment arms to compare the effect of Pycnogenol® to MPH and placebo on the behaviour of 144 paediatric ADHD and attention-deficit disorder (ADD) patients. Evaluations of behaviour (measured by the ADHD-Rating Scale (primary endpoint) and the Social-emotional Questionnaire (SEQ)), immunity (plasma cytokine and antibody levels, white blood cell counts and faecal microbial composition), oxidative stress (erythrocyte glutathione, plasma lipid-soluble vitamins and malondialdehyde and urinary 8-OHdG levels, as well as antioxidant enzyme activity and gene expression), serum zinc and neuropeptide Y level, urinary catecholamines and physical complaints (Physical Complaints Questionnaire) will be performed in week 10 and compared to baseline. Acceptability evaluations will be based on adherence, dropouts and reports of adverse events. Dietary habits will be taken into account.

Discussion: This trial takes into account comorbid behavioural and physical symptoms, as well as a broad range of innovative immune and oxidative biomarkers, expected to provide fundamental knowledge on ADHD aetiology and therapy. Research on microbiota in ADHD is novel. Moreover, the active control arm is rather unseen in research on nutritional supplements, but of great importance, as patients and parents are often concerned with the side effects of MPH.

Trial registration: Clinicaltrials.gov number: NCT02700685 . Registered on 18 January 2016. EudraCT 2016-000215-32 . Registered on 4 October 2016.

Keywords: ADD; ADHD; Antioxidant; Behaviour; Catecholamines; Immunity; Oxidative stress; Polyphenols; Pycnogenol®.

Figures

Fig. 1
Fig. 1
Design of the trial

References

    1. Pelham WE, Foster EM, Robb JA. The economic impact of attention-deficit/hyperactivity disorder in children and adolescents. J Pediatr Psychol. 2007;32(6):711–727. doi: 10.1093/jpepsy/jsm022.
    1. Polanczyk GV, et al. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. Int J Epidemiol. 2014;43(2):434–442. doi: 10.1093/ije/dyt261.
    1. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366:237–248. doi: 10.1016/S0140-6736(05)66915-2.
    1. Antshel KM, et al. Advances in understanding and treating ADHD. BMC Med. 2011;9:72. doi: 10.1186/1741-7015-9-72.
    1. Claes S, et al. Het toenemend gebruik van psychofarmaca. Visietekst werkgroep Metaforum Leuven. 2010.
    1. Schachter HM, et al. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis CMAJ. 2011;165(11):1475–1488.
    1. Steer CR, Suppl I. Managing attention deficit/hyperactivity disorder: unmet needs and future directions. Arch Dis Child. 2005;90:i19–i25. doi: 10.1136/adc.2004.059352.
    1. Storebø OJ, et al. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials. BMJ. 2015;351:h5203. doi: 10.1136/bmj.h5203.
    1. Ceylan M, et al. Changes in oxidative stress and cellular immunity serum markers in attention-deficit/hyperactivity disorder. Psychiatry Clin Neurosci. 2012;66:220–226. doi: 10.1111/j.1440-1819.2012.02330.x.
    1. Pelsser LMJ, Buitelaar JK, Savelkoul HFJ. ADHD as a (non) allergic hypersensitivity disorder: a hypothesis. Pediatr Allergy Immunol. 2009;20(2):107–112. doi: 10.1111/j.1399-3038.2008.00749.x.
    1. Ceylan M, et al. Oxidative imbalance in child and adolescent patients with attention-deficit/hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(8):1491–1494. doi: 10.1016/j.pnpbp.2010.08.010.
    1. El Adham EK, Hassan AI, El Aziz El-Mahdy AA. Nutritional and metabolic disturbances in attention deficit hyperactivity disease. Res J Med Med Sci. 2011;6(1):10–6.
    1. Ross BM, et al. Increased levels of ethane, a non-invasive marker of n-3 fatty acid oxidation, in breath of children with attention deficit hyperactivity disorder. Nutr Neurosci. 2003;6(5):277–281. doi: 10.1080/10284150310001612203.
    1. Kawatani M, Tsukahara H, Mayumi M. Evaluation of oxidative stress status in children with pervasive developmental disorder and attention deficit hyperactivity disorder using urinary-specific biomarkers. Redox Rep. 2011;16(1):45–46. doi: 10.1179/174329211X12968219310873.
    1. Güngör S, et al. The frequency of celiac disease in attention-deficit hyperactivity disorder. J Pediatr Gastroenterol Nutr. 2013;56(2):211–214. doi: 10.1097/MPG.0b013e318272b7bc.
    1. Minter K, et al. Early childhood otitis media in relation to children’s attention-related behavior in the first six years of life. Pediatrics. 2001;107:1037–1042. doi: 10.1542/peds.107.5.1037.
    1. Schmitt J, Buske-Kirschbaum A, Roessner V. Is atopic disease a risk factor for attention-deficit/hyperactivity disorder? A systematic review. Allergy. 2010;65(12):1506–1524. doi: 10.1111/j.1398-9995.2010.02449.x.
    1. Tsai SJ. Signal transducer and activator of transcription 6 (STAT6) and attention-deficit hyperactivity disorder: a speculative hypothesis. Med Hypoth. 2006;67(6):1341–1343. doi: 10.1016/j.mehy.2006.05.019.
    1. Furlano R, et al. Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. J Pediatr. 2001;138(3):366–372. doi: 10.1067/mpd.2001.111323.
    1. Noriega DB, Savelkoul HFJ. Immune dysregulation in autism spectrum disorder. Eur J Ped. 2014;173(1):33–43. doi: 10.1007/s00431-013-2183-4.
    1. Verlaet AAJ, et al. Nutrition, immunological mechanisms and dietary immunomodulation in ADHD. Eur Child Adolesc Psychiatry. 2014;23(7):519–529. doi: 10.1007/s00787-014-0522-2.
    1. Trebatická J, et al. Treatment of ADHD with French maritime pine bark extract. Pycnogenol Eur Child Adolesc Psychiatry. 2006;15:329–335. doi: 10.1007/s00787-006-0538-3.
    1. D’Andrea G. Pycnogenol: a blend of procyanidins with multifaceted therapeutic applications? Fitoterapia. 2010;81:724–736. doi: 10.1016/j.fitote.2010.06.011.
    1. Wilson D, et al. A randomized, double-blind, placebo-controlled exploratory study to evaluate the potential of Pycnogenol for improving allergic rhinitis symptoms. Phytother Res. 2010;24(8):1115–1119.
    1. Chovanová Z, et al. Effect of polyphenolic extract, Pycnogenol, on the level of 8-oxoguanine in children suffering from attention deficit/hyperactivity disorder. Free Radical Res. 2006;40:1003–1010. doi: 10.1080/10715760600824902.
    1. Dvořáková M, et al. The effect of polyphenolic extract from pine bark, Pycnogenol, on the level of glutathione in children suffering from attention deficit hyperactivity disorder (ADHD) Redox Rep. 2006;11:163–172. doi: 10.1179/135100006X116664.
    1. Tenenbaum S, et al. An experimental comparison of Pycnogenol and methylphenidate in adults with attention-deficit/hyperactivity disorder (ADHD) J Atten Disord. 2002;6:49–60. doi: 10.1177/108705470200600201.
    1. Greenblatt J. Nutritional supplements in ADHD. J Am Acad Child Adolesc Psychiatry. 1999;38:1209–1210. doi: 10.1097/00004583-199910000-00005.
    1. Heimann SW. Pycnogenol for ADHD? J Am Acad Child Adolesc Psychiatry. 1999;38:357–358. doi: 10.1097/00004583-199904000-00006.
    1. Jennings CG, et al. Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants? Trials. 2015;16:80. doi: 10.1186/s13063-015-0582-8.
    1. Kerkhoff LA, et al. Trends in consent for clinical trials in cardiovascular disease. J Am Heart Assoc. 2016;5(6):e003582. doi: 10.1161/JAHA.116.003582.
    1. Buitelaar JK, Montgomery SA, van Zwieten-Boot BJ. Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention. Eur Neuropsychopharmacol. 2003;13:297–304. doi: 10.1016/S0924-977X(03)00047-6.
    1. TestWeb. Sociaal-Emotionele Vragenlijst (SEV). 2013. Available from: . Accessed date: 15 Dec 2016.
    1. Pelsser LMJ, Buitelaar JK. Favourable effect of a standard elimination diet on the behaviour of young children with attention deficit-hyperactivity disorder (ADHD), a pilot study. Ned Tijdschr Geneesk. 2002;46(52):2543–2547.
    1. Pastore A, et al. Analysis of glutathione: implication in redox and detoxification. Clin Chim Acta. 2003;333(1):19–39. doi: 10.1016/S0009-8981(03)00200-6.
    1. Conaway HH, Henning P, Lerner UH. Vitamin a metabolism, action, and role in skeletal homeostasis. Endocr Rev. 2013;34:766–797. doi: 10.1210/er.2012-1071.
    1. Naguib Y, et al. Antioxidant activities of natural vitamin E formulations. J Nutr Sci Vitaminol. 2003;49:217–220. doi: 10.3177/jnsv.49.217.
    1. Littarru GP, Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol. 2007;37:31–7.
    1. Molyneux SL, et al. Coenzyme Q10: is there a clinical role and a case for measurement? Clin Biochem Rev. 2008;29(2):71–82.
    1. Sezen H, et al. Increased oxidative stress in children with attention deficit hyperactivity disorder. Redox Rep. 2016;21(6):248–253. doi: 10.1080/13510002.2015.1116729.
    1. Franceschi C, et al. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev. 2005;126(2):351–361. doi: 10.1016/j.mad.2004.08.028.
    1. Rahman I, Yang SR, Biswas SK. Current concepts of redox signaling in the lungs. Antioxid Redox Signal. 2006;8:681–689. doi: 10.1089/ars.2006.8.681.
    1. Whitehouse RC, et al. Zinc in plasma, neutrophils, lymphocytes, and erythrocytes as determined by flameless atomic absorption spectrophotometry. Clin Chem. 1982;28(3):475–480.
    1. Aruoma OI. Free radicals, oxidative stress, and antioxidants in human health and disease. JAOCS. 1998;75:199–212.
    1. Dalle-Donne I, et al. Biomarkers of oxidative damage in human disease. Clin Chem. 2006;52:601–623. doi: 10.1373/clinchem.2005.061408.
    1. Furukawa T, Meydani SN, Blumberg JB. Reversal of age-associated decline in immune responsiveness by dietary glutathione supplementation in mice. Mech Ageing Dev. 1987;38(2):107–117. doi: 10.1016/0047-6374(87)90071-6.
    1. Grimm T, et al. Inhibition of NF-κB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). J Inflam. 2006;3(1):1–6.
    1. Booijink CC, et al. High temporal and inter-individual variation detected in the human ileal microbiota. Environ Microbiol. 2010;12(12):3213–3227. doi: 10.1111/j.1462-2920.2010.02294.x.
    1. González TJB, et al. Study of the aminoglycoside subsistence phenotype of bacteria residing in the gut of humans and zoo animals. Front Microbiol. 2015;6:1–7.
    1. Dvořáková M, et al. Urinary catecholamines in children with attention deficit hyperactivity disorder (ADHD): modulation by a polyphenolic extract from pine bark (Pycnogenol) Nutr Neurosci. 2007;10:151–157. doi: 10.1080/09513590701565443.
    1. Ozcan O, et al. Plasma leptin, adiponectin, neuropeptide Y levels in drug naive children with ADHD. J Atten Disord. 2015 [Epub ahead of print].
    1. de Vriese S, et al. The Belgian food consumption survey: aims, design and methods. Archives Public Health. 2005;63:1–16.
    1. De Keyzer W, et al. Relative validity of a short qualitative food frequency questionnaire for use in food consumption surveys. Eur J Public Health. 2012;23(5):737–742. doi: 10.1093/eurpub/cks096.
    1. Pelsser LMJ, et al. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study): a randomised controlled trial. Lancet. 2011;377:494–503. doi: 10.1016/S0140-6736(10)62227-1.
    1. Berek M, et al. Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents? Child Adolesc Psych Ment Health. 2011;5(26):1–13.
    1. Christensen E. Methodology of superiority vs. equivalence trials and non-inferiority trials. J Hepatol. 2007;46:947–954. doi: 10.1016/j.jhep.2007.02.015.
    1. Piaggio G, et al. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295:1152–1160. doi: 10.1001/jama.295.10.1152.
    1. Power TJ, et al. The predictive validity of parent and teacher reports of ADHD symptoms. J Psychopathol Behav Assess. 1998;20(1):57–81. doi: 10.1023/A:1023035426642.
    1. Tripp G, Schaughency EA, Clarke B. Parent and teacher rating scales in the evaluation of attention-deficit hyperactivity disorder: contribution to diagnosis and differential diagnosis in clinically referred children. J Dev Behav Pediatr. 2006;27(3):209–218. doi: 10.1097/00004703-200606000-00006.
    1. Rohdewald PJ. Pycnogenol, French maritime pine bark extract. In: Coates PM, Blackman MR, Cragg GM, Levine M, Moss J, White JD, editors. Encyclopedia of Dietary Supplements. New York, Marcel Dekker, Inc.; 2005;545–53.
    1. Belkaid Y, Hand T. Role of the microbiota in immunity and inflammation. Cell. 2014;157:121–141. doi: 10.1016/j.cell.2014.03.011.
    1. Cardona F, et al. Benefits of polyphenols on gut microbiota and implications in human health. J Nutr Biochem. 2013;24(8):1415–1422. doi: 10.1016/j.jnutbio.2013.05.001.
    1. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther. 2002;40(4):158–168. doi: 10.5414/CPP40158.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe